ReviewFuture microbiology2020
Focus on the 2019 novel coronavirus (SARS-CoV-2).
Review in Future microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Face Mask in COVID-19 and Its Association With Dry Eye Disease: A Cross-Sectional Study.Cureus · 2022Article
- Assessment of SARS-CoV-2 Infection According to Previous Metabolic Status and Its Association with Mortality and Post-Acute COVID-19.Nutrients · 2022Article
- Understanding Health Communication Through Google Trends and News Coverage for COVID-19: Multinational Study in Eight Countries.JMIR public health and surveillance · 2021Article
- SARS-CoV-2 as a betacoronavirus comprises five structural proteins?Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021Article
- Severe Lymphopenia as a Predictor of COVID-19 Mortality in Immunosuppressed Patients.Journal of clinical medicine · 2021Article
- Review
- Post-Mortem Detection of SARS-CoV-2 RNA in Long-Buried Lung Samples.Diagnostics (Basel, Switzerland) · 2021Article
- Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!BMC research notes · 2021Article
- Transnasal endoscopic skull base surgery in the COVID-19 era: Recommendations for increasing the safety of the method.Advances in medical sciences · 2021Review
- Prevalence of opportunistic invasive aspergillosis in COVID-19 patients with severe pneumonia.Mycoses · 2021Observational
- The Long-Term Evolutionary History of Gradual Reduction of CpG Dinucleotides in the SARS-CoV-2 Lineage.Biology · 2021Article
- Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights.Redox biology · 2021Review
- Protecting Healthcare Workers Amid the COVID-19 Crisis: A Safety Protocol in Wuhan.Frontiers in public health · 2020Article
- Coronavirus disease 2019 (COVID-19): diagnosis and prognosis.Blood and genomics · 2020Article
- Inflammatory-Related Clinical and Metabolic Outcomes in COVID-19 Patients.Mediators of inflammation · 2020Article
- Quercetin may reduce the risk of developing the symptoms of COVID-19.Avicenna journal of phytomedicineReview
- Article
Corrections and comments
- Erratum issuedCorrigendum.2021
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A new coronavirus, severe acute respiratory syndrome coronavirus 2, was first discovered in Wuhan, China, in December 2019. As of 7 April 2020, the new coronavirus has spread quickly to 184 countries and aroused the attention of the entire world. No targeted drugs have yet been available for intervention and treatment of this virus. The sharing of academic information is crucial to risk assessment and control activities in outbreak countries. In this review, we summarize the epidemiological, genetic and clinical characteristics of the virus as well as laboratory testing and treatments to understand the nature of the virus. We hope this review will be helpful to prevent viral infections in outbreak countries and regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.